More Genetic Clues Needed to Improve Lung Cancer Treatment

David Spigel, a lung cancer specialist, explains the potential of biomarkers in the search for new treatments.

David Spigel, director of the Lung Cancer Research Program at Sarah Cannon Research Institute in Nashville, answers CURE's questions on how biomarkers will affect lung cancer treatment now and in the future.

Podcast: David Spigel and the future of lung cancer biomarkers

While only a fraction of lung cancer mutations have a treatment that targets them, Spigel expects that in the near future, many more genetic clues will be uncovered. These discoveries will help shape treatment decisions for a wider range of patients.